Earnings pressure on the dispensing business from revisions to medical service fees and drug prices
First written in FY2017-Q1. 5 of 6 entries say "Restated". Latest entry: FY2019-Q3.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2019-Q3RestatedAnnual report
「In the business, food, pharmaceuticals and cosmetics performed strongly, while the pharmacy division remained resilient despite the effects of revisions to medical service fees, and same-store sales increased 3.9% year on year.」
Although the effects of revisions to medical service fees continued, the pharmacy division remained resilient, and higher same-store sales and a lower expense ratio resulted in higher revenue and higher profit. - FY2019-Q1RestatedAnnual report
「Although the business was affected by revisions to medical service fees, the pharmacy division remained resilient and same-store sales increased 2.8% year on year. Contributions from stores opened from the previous fiscal year through the current fiscal year helped reduce the expense ratio, resulting in higher revenue and higher profit.」
Although the effects of revisions to medical service fees continued, higher revenue and higher profit were secured through the resilience of the pharmacy division, a 2.8% increase in same-store sales, and a lower expense ratio. - FY2017RestatedAnnual report
「Amid continuing effects from lower drug prices and changes to the fee structure accompanying revisions to medical service fees, strong sales of pharmaceuticals and cosmetics improved the gross profit margin. However, higher store-opening expenses and other costs resulted in higher revenue but lower profit.」
The effects of lower drug prices and changes to the fee structure continued, and although sales of pharmaceuticals and cosmetics improved the gross profit margin, the Drugstore Business posted higher revenue but lower profit due to store-opening expenses and other costs. - FY2017-Q3RestatedAnnual report
「Although the effects of lower drug prices and changes to the fee structure accompanying revisions to medical service fees continued, strong sales of pharmaceuticals and cosmetics improved the gross profit margin. Stores opened from the previous fiscal year through the current fiscal year also contributed, resulting in higher revenue and higher profit.」
Although the effects of lower drug prices and changes to the fee structure continued, the Drugstore Business posted higher revenue and higher profit, supported by sales of pharmaceuticals and cosmetics and contributions from stores. - FY2017-Q2RestatedAnnual report
「Lower drug prices and changes to the fee structure accompanying revisions to medical service fees affected the pharmacy division's sales and gross profit margin, resulting in higher revenue but lower profit.」
The pharmacy division continues to face pressure on earnings from revisions to medical service fees, lower drug prices and changes to the fee structure. - FY2017-Q1MaterialisedAnnual report
「Lower drug prices and changes to the fee structure accompanying revisions to medical service fees affected the pharmacy division's sales growth rate and gross profit margin, resulting in higher revenue but lower profit.」
Revisions to medical service fees, lower drug prices and changes to the fee structure are newly identified risk factors that have actually affected the pharmacy division's sales growth rate and gross profit margin.